First Time Loading...
S

StemRIM Inc
TSE:4599

Watchlist Manager
StemRIM Inc
TSE:4599
Watchlist
Price: 475 JPY 0.42% Market Closed
Updated: May 3, 2024
Section:
 

Relative Value

The Relative Value of one StemRIM Inc stock under the Base Case scenario is 103.35 JPY. Compared to the current market price of 475 JPY, StemRIM Inc is Overvalued by 78%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
103.35 JPY
Overvaluation 78%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

12.4
P/S
P/S
Price to Sales
12.4
vs History
71
vs Industry
42
Median 3Y
23.9
Median 5Y
20.7
Industry
8.1
Forward
28.9
More Details
162.8
P/E
P/E
Price to Earnings
162.8
vs History
25
vs Industry
0
Median 3Y
-27.9
Median 5Y
-28.1
Industry
26.2
Forward
-22.2
More Details
47.8
P/OCF
P/OCF
Price to OCF
47.8
vs History
16
vs Industry
4
Median 3Y
-38.2
Median 5Y
-60.8
Industry
22.6
More Details
48.2
P/FCFE
P/FCFE
Price to FCFE
48.2
vs History
16
vs Industry
4
Median 3Y
-38.1
Median 5Y
-51.6
Industry
21.3
More Details
3
P/B
P/B
Price to Book Value
3
vs History
89
vs Industry
32
Median 3Y
4.6
Median 5Y
4.6
Industry
2.5
More Details
8.5
EV/S
EV/S
Enterprise Value to Sales
8.5
vs History
71
vs Industry
42
Median 3Y
18.3
Median 5Y
16.4
Industry
7.3
Forward
19.8
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.1
More Details
101.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
101.7
vs History
25
vs Industry
1
Median 3Y
-23.4
Median 5Y
-24.3
Industry
4.4
Forward
-15.4
More Details
132.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
132.7
vs History
25
vs Industry
0
Median 3Y
-22.9
Median 5Y
-23.7
Industry
4.3
More Details
32.8
EV/OCF
EV/OCF
Enterprise Value to OCF
32.8
vs History
20
vs Industry
5
Median 3Y
-32.3
Median 5Y
-41.8
Industry
5.4
More Details
32.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
32.9
vs History
20
vs Industry
5
Median 3Y
-32.3
Median 5Y
-37.9
Industry
3.2
More Details
22.8
EV/IC
EV/IC
Enterprise Value to IC
22.8
vs History
88
vs Industry
13
Median 3Y
47.6
Median 5Y
52.8
Industry
5
More Details

Multiples Across Competitors

Competitors Multiples
StemRIM Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
StemRIM Inc
TSE:4599
29.2B JPY 12.4 162.8 101.7 132.7
US
Abbvie Inc
NYSE:ABBV
286B USD 5.3 59.3 12.9 19.7
US
Amgen Inc
NASDAQ:AMGN
167.1B USD 5.9 24.9 17.9 26.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.8B USD 10.4 28.3 22.7 23.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
102.9B USD 7.8 26 17.5 19.2
AU
CSL Ltd
ASX:CSL
133.2B AUD 6.2 35.4 21.5 26.6
US
Gilead Sciences Inc
NASDAQ:GILD
80.4B USD 2.9 165.9 6.7 8.7
US
Moderna Inc
NASDAQ:MRNA
47.3B USD 7 -10.1 -10.9 -9.3
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.2B USD 3.2 26.8 13.7 17.2
KR
Celltrion Inc
KRX:068270
39.2T KRW 18 73.1 44.7 61.6
EV/EBITDA Multiple
EBITDA Growth
JP
S
StemRIM Inc
TSE:4599
Average EV/EBITDA: 28.8
101.7
N/A
US
Abbvie Inc
NYSE:ABBV
12.9
26%
US
Amgen Inc
NASDAQ:AMGN
17.9
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
50%
AU
CSL Ltd
ASX:CSL
21.5
54%
US
Gilead Sciences Inc
NASDAQ:GILD
6.7
18%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -10.9 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Biogen Inc
NASDAQ:BIIB
13.7
67%
KR
Celltrion Inc
KRX:068270
44.7
109%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.